Market Introduction
Hematuria is a medical condition where presence of blood is found in the urine. Generally, urine does not contain RBC and hence this can result in serious issue that may also cause kidney stones, urinary tract infection and other inherited diseases.
Moreover, the high prevalence hematuria associated indications is expected to bolster the market growth during the forecast period. However, undiagnosed cases of associated indications limit the growth of the South & Central America hematuria treatment market.
The SARS-CoV-2 pandemic had a sudden, dramatic impact on the healthcare of the SCAM region. The COVID-19 pandemic has shifted the accepted and routine treatment of elective cases in hospital administration. South and Central America are no exception. Strict social distancing procedures now apply, with patients being admitted to the clinic unaccompanied and individually. CoViD-19 has changed everyday life almost all over the world. Overall, the magnitude of this disruption is due to individual fears and government-level actions relative to the local impact of the pandemic. However, there may be times when restrictive measures are put in place in the early stages, when the rapid evolution of the problem is unknown, to ensure the community's health. In Argentina, this was the situation that paralyzed programmed medical care. Such restrictions are likely to have a negative impact on the research and development activities, which would directly restrain the growth of the hematuria treatment market in the region.
Market Overview and Dynamics
The South & Central America hematuria treatment market is projected to reach US$ 65.7 million by 2028 from US$ 57.8 million in 2021; it is anticipated to grow at a CAGR of 1.8% from 2021 to 2028. Technological developments in medical devices and diagnostic procedures have led to various options for managing hematuria-associated indications, such as kidney stones, bladder stones, and urinary tract infections. The use of advanced treatment technologies is expected to enhance patient care. For instance, the implementation of robotics in surgeries for treating urolithiasis has gained popularity in recent years. Currently, Vinci Surgical System, by Intuitive Surgical Inc., is widely used in performing surgeries to treat urolithiasis. Similarly, the uptake of endourological interventions for kidney stones has increased significantly across various countries. It is also expected that advancements in associated indications are likely to support the South & Central America hematuria treatment market during the forecast period.
Key Market Segments
In terms of type, the macroscopic hematuria segment accounted for the largest share of the South & Central America hematuria treatment market in 2020. In terms of treatment, the drugs segment accounted for the largest share of the South & Central America hematuria treatment market in 2020. In terms of indication, the urinary tract infection segment accounted for the largest share of the South & Central America hematuria treatment market in 2020. In terms of end user, the hospitals segment accounted for the largest share of the South & Central America hematuria treatment market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the hematuria treatment market in South & Central America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd, and Boehringer Ingelheim International GmbH.
Reasons to Buy Report
- To understand the South & Central America hematuria treatment market landscape and identify market segments that are likely to guarantee a strong return
- To comprehend the ever-changing market landscape and stay ahead in competition
- To efficiently plan merger and acquisition, and partnership deals in the South & Central America hematuria treatment market by identifying segments with the most promising probable sales
- To make knowledgeable business decisions from perceptive and comprehensive analysis of the market performance of various segments
- To obtain market revenue forecast of the South & Central America hematuria treatment market based on various segments for the period 2021–2028
SOUTH & CENTRAL AMERICA HEMATURIA TREATMENT MARKET SEGMENTATION
- Drugs
- Therapies
- Others
By Indication
- Urinary Tract Infections
- Kidney Stones
- Urethritis
- Blood Cancer
- Bladder Stones
- Prostate Cancer
- Cystitis
- Trauma
- Vigorous Exercise
- Polycystic Kidney Disease
- Endometriosis
- Menstruation
By Type
- Macroscopic Hematuria
- Microscopic Hematuria
- Idiopathic Hematuria
- Jogger’s Hematuria
By End User
- Hospitals
- Clinics
- Ambulatory Surgical Centers (ASC's)
- Others
By Country
-
South & Central America
- Brazil
- Argentina
- Rest of South & Central America
Companies Mentioned
- AstraZeneca
- Bristol-Myers Squibb Company
- F. HOFFMANN-LA ROCHE LTD.
- GlaxoSmithKline plc.
- Janssen Pharmaceuticals
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Boehringer Ingelheim International GmbH
South & Central America Hematuria Treatment Market Strategic Insights
South & Central America Hematuria Treatment Market Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$ 57.8 Million |
| Market Size by 2028 | US$ 65.7 Million |
| CAGR (2021 - 2028) | 1.8% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Treatment
|
|
Regions and Countries Covered
|
|
| South and Central America | Brazil, Argentina, Rest of South and Central America |
| Market leaders and key company profiles |
|
South & Central America Hematuria Treatment Market Country and Regional Insights
